Replies to post #46 on Equity Field Notes from temporal sources

[DanWebzster]

Mitochondrial Peptides and CWBR:

[DanWebzster]

PRTK (update)

raised capital 2x so far in 2018, further depressing the stock price

raised $50mn with a secondary offering 1/18

raised raised $140mn plus an option for an additional $25 with a senior debt issuance 4/18

There is one additional factor that may enhance omadacycline's chances for approval in October. Unlike other broad spectrum antibiotics, treated patients do not get infected with C-dif and do not suffer from diarrhea.